Novel data-driven approach improves disease progression scales in Parkinson's disease, enhancing clinical trials' effectiveness.
Parkinson's disease is a highly heterogeneous condition with symptoms spanning motor and non-motor domains. Clinical scales like the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS), are standard in clinical trials where disease progression is monitored. They rely on summing item values, assuming uniform item importance and score increments. Here we propose a novel data-driven approach to optimize weights for such scales - so that total scores better reflect the underlying disease severity. By leveraging large-scale longitudinal data from the Parkinson's Progression Markers Initiative (PPMI), our methods identified which items (and value increments) most strongly indicate PD progression, down-weighting or excluding less informative items. The learned weights substantially improve the monotonic relationship between total scores and clinical progression. We validated our weights using both held-out PPMI data and an independent dataset (BeaT-PD), demonstrating their robustness. Applying such weights in clinical trials may increase power and reduce the required sample size.
No takes yet. Share an insight, caveat, or question.
Benesh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: